Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Managing the toxicities of doublet ADC therapy in urothelial carcinoma

Randy Sweis, MD, University of Chicago, Chicago, IL, comments on the potential of combining two antibody-drug conjugates (ADCs) in urothelial carcinoma, which was assessed in the TROPHY-U-01 trial (NCT03547973). The reduced dose of one agent and mandated use of GCSF helped mitigate toxicities, and while neuropathy was a prevalent toxicity, it was manageable and did not exceed expectations based on prior combinations. The doublet regimen has non-overlapping toxicities that can be mitigated with dose adjustments and careful patient monitoring. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Certainly, there was a concern that combining the two ADCs would lead to intolerable toxicities, but I think this study provides evidence that that’s not the case. The dose of SG, again, was reduced to 7.5 milligrams compared with the monotherapy dose of 10 milligrams per kilogram, so that helped. And also, the use of GCSF was mandated on this study, which prevented or mitigated the risk of neutropenic fever and neutropenic toxicity...

Certainly, there was a concern that combining the two ADCs would lead to intolerable toxicities, but I think this study provides evidence that that’s not the case. The dose of SG, again, was reduced to 7.5 milligrams compared with the monotherapy dose of 10 milligrams per kilogram, so that helped. And also, the use of GCSF was mandated on this study, which prevented or mitigated the risk of neutropenic fever and neutropenic toxicity. I mentioned three patients had neutropenia that was grade three. Those were all short-lived occurring in cycle one. And there was one DLT of neutropenic fever that was less than 24 hours. But nonetheless, patients were able to stay on therapy. And the toxicity of neuropathy was prevalent and actually did lead to discontinuation of inotuzumab-vedotin. But it didn’t seem to be beyond what is seen with inotuzumab plus pembrolizumab. So I think that the doublet has a lot of non-overlapping toxicity and can be mitigated with dose adjustments and careful monitoring of patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.